Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 58, Issue 2, 2004, Pages 265-278

  Lindenberg, Marc ^a   Kopp, Sabine ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Absorption; Biopharmaceutical classification system; Essential Medicines; Permeability; Solubility; World Health Organization

Indexed keywords

ABACAVIR; ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ACICLOVIR; ALBENDAZOLE; ALLOPURINOL; ATENOLOL; BENZNIDAZOLE; CARBAMAZEPINE; CHLOROQUINE; CIMETIDINE; CIPROFLOXACIN; DIAZEPAM; DOXYCYCLINE; ERYTHROMYCIN; FUROSEMIDE; GLIBENCLAMIDE; GRISEOFULVIN; IBUPROFEN; LEVOTHYROXINE; MEBENDAZOLE; METRONIDAZOLE; NICLOSAMIDE; PENICILLIN V; PHENYTOIN; PROPRANOLOL; RIFAMPICIN; RITONAVIR; SULFADIAZINE; UNINDEXED DRUG;

DRUG ABSORPTION; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; BIOLOGICAL PRODUCTS; BIOPHARMACEUTICS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEGISLATION, DRUG; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; WORLD HEALTH ORGANIZATION;

EID: 3843097202     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2004.03.001     Document Type: Review

References (284)

1. FDA. Waiver of in vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms based on a Biopharmaceutics Classification System. 2000
2. Horter D., Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46:2001;75-87
3. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46:2001;27-43
4. Various Authors, USP 26: Board of Trustees, Rockville, MD, 2003.
5. Chittick G.E., Gillotin C., McDowell J.A., Lou Y., Edwards K.D., Prince W.T., Stein D.S. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food. Pharmacotherapy. 19:1999;932-942
6. McDowell J.A., Chittick G.E., Ravitch J.R., Polk R.E., Kerkering T.M., Stein D.S. Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43:1999;2855-2861
7. Trizivir™ prescribing information, Glaxo Smith Kline.
8. Safety data sheet: http://www.chemicalland21.com/arokorhi/lifescience/ phar/acetylsalicylic%20acid.htm.
9. Ito S., Oka R., Tsuchida A., Yoshioka H. Disposition of single-dose intravenous and oral aspirin in children. Dev. Pharmacol. Ther. 17:1991;180-186
10. Needs C.J., Brooks P.M. Clinical pharmacokinetics of the salicylates. Clin. Pharmacokinet. 10:1985;164-177
11. Schroder H., Schror K. Clinical pharmacology of acetylsalicylic acid. Z. Kardiol. 81:(Suppl. 4):1992;171-175
12. Sweetman S.C. Martindale 33. Martindale The Extra Pharmacopoeia. 2002;Council of the Royal Pharmaceutical Society of Great Britain, London
13. Pedersen A.K., FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311:1984;1206-1211
14. Day R.O., Paull P.D., Champion G.D., Graham G.G. Evaluation of an enteric coated aspirin preparation. Aust. N. Z. J. Med. 6:1976;45-50
15. Paull P., Day R., Graham G., Champion D. Single-dose evaluation of a new enteric-coated aspirin preparation. Med. J. Aust. 1:1976;617-619
16. Various Authors, Analytical Profiles of Drug Substances: K. Florey, Academic Press, Inc., New York, 1972.
17. Bergstrom C.A., Norinder U., Luthman K., Artursson P. Experimental and computational screening models for prediction of aqueous drug solubility. Pharm. Res. 19:2002;182-188
18. McKinney P.E., Gillilan R., Watson W.A. The preadministration of activated charcoal and aspirin absorption. J. Toxicol. Clin. Toxicol. 30:1992;549-556
19. Bras A.P., Sitar D.S., Aoki F.Y. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can. J. Clin. Pharmacol. 8:2001;207-211
20. de Miranda P., Blum M.R. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12:(Suppl. B):1983;29-37
21. Morse G.D., Shelton M.J., O'Donnell A.M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. 24:1993;101-123
22. Laskin O.L. Clinical pharmacokinetics of acyclovir. Clin. Pharmacokinet. 8:1983;187-201
23. Joel G. Hardman, Goodman and Gilman The Pharmacological Basis of Therapeutics, McGraw-Hill Professional, 2001.
24. A. Avdeef, Determination of drug solubility using a potentiometric acid-base titration method compared to the saturation shake-flask method: http://www.pion-inc.com/images/aaps00_solubility1.pdf.
25. Data on file.
26. Appelbaum S.J., Mayersohn M., Dorr R.T., Perrier D. Allopurinol kinetics and bioavailability. Intravenous, oral and rectal administration. Cancer Chemother. Pharmacol. 8:1982;93-98
27. Breithaupt B., Tittel M. Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide. Eur. J. Clin. Pharmacol. 22:1982;77-84
28. Murrell G.A., Rapeport W.G. Clinical pharmacokinetics of allopurinol. Clin. Pharmacokinet. 11:1986;343-353
29. Turnheim K., Krivanek P., Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br. J. Clin. Pharmacol. 48:1999;501-509
30. Budavari S. The Merck Index 12. The Merck Index. 1996;Merck Research Laboratories, Whitehouse Station, NJ
31. Klopp D.T. Pharmazeutische Stoffliste. 2002;ABDA, Eschborn/Germany
32. Artur Burger H.W. Hunnius. 1998;Walter de Gruyter&Co, Berlin
33. German Fachinfo: Eryhexal®, Hexal AG; Myambutol Filmtabletten®, Riemser; Sustiva®, Bristol-Myers Squibb; Methionin-ratiopharm®, Ratiopharm AG; Vitamin B1-ratiopharm®, Ratiopharm AG; Biofanal Dragees®, Pfleger; Nicobion®, Merck KGaA; Inivirase®, Hoffmann-La Roche; Frubiase calcium forte 500®, Boehringer Ingelheim; Riamet®, Novartis Pharma, Teplite®, ICN.
34. Priest N.D., Talbot R.J., Austin J.G., Day J.P., King S.J., Fifield K., Cresswell R.G. The bioavailability of 26Al-labelled aluminium citrate and aluminium hydroxide in volunteers. Biometals. 9:1996;221-228
35. Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol. Toxicol. (Copenh). 54:(Suppl. 1):1984;17-29
36. Lennernas H., Knutson L., Knutson T., Hussain A., Lesko L., Salmonson T., Amidon G.L. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur. J. Pharm. Sci. 15:2002;271-277
37. Kallner A., Hartmann D., Hornig D. On the absorption of ascorbic acid in man. Int. J. Vitam. Nutr. Res. 47:1977;383-388
38. DPHG. GSP, Gute Substitutions Praxis: http://www.dphg.de/lib/ dphg_leitlinie01_gsp_02-1.pdf.
39. Kirch W., Gorg K.G. Clinical pharmacokinetics of atenolol - a review. Eur. J. Drug Metab. Pharmacokinet. 7:1982;81-91
40. Lennernas H., Ahrenstedt O., Ungell A.L. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. Br. J. Clin. Pharmacol. 37:1994;589-596
41. a determination of drugs using pressure-assisted capillary electrophoresis with photodiode array detection in drug discovery. J. Pharm. Sci. 91:2002;933-942
42. Fagerholm U., Johansson M., Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 13:1996;1336-1342
43. Duchin K.L., Singhvi S.M., Willard D.A., Migdalof B.H., McKinstry D.N. Captopril kinetics. Clin. Pharmacol. Ther. 31:1982;452-458
44. Duchin K.L., McKinstry D.N., Cohen A.I., Migdalof B.H. Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. Clin. Pharmacokinet. 14:1988;241-259
45. Gerardin A., Dubois J.P., Moppert J., Geller L. Absolute bioavailability of carbamazepine after oral administration of a 2% syrup. Epilepsia. 31:1990;334-338
46. Mandagere A.K., Thompson T.N., Hwang K.K. Graphical model for estimating oral bioavailability of drugs in humans and other species from their Caco-2 permeability and in vitro liver enzyme metabolic stability rates. J. Med. Chem. 45:2002;304-311
47. Ambrose P.J. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin. Pharmacokinet. 9:1984;222-238
48. Kramer W.G., Rensimer E.R., Ericsson C.D., Pickering L.K. Comparative bioavailability of intravenous and oral chloramphenicol in adults. J. Clin. Pharmacol. 24:1984;181-186
49. Gustafsson L.L., Walker O., Alvan G., Beermann B., Estevez F., Gleisner L., Lindstrom B., Sjoqvist F. Disposition of chloroquine in man after single intravenous and oral doses. Br. J. Clin. Pharmacol. 15:1983;471-479
50. Katrukha S.P., Karpenko E.V., Davydov S.M., Blinkov I.L., Kukes V.G. Cimetidine pharmacokinetics. Farmakol. Toksikol. 49:1986;36-40
51. Kawai K. Does H2 receptor antagonist-resistant ulcer exist? A review based on bioavailability in man. Gastroenterol. Jpn. 27:1992;418-423
52. Pedersen P.V., Miller R. Pharmacokinetics and bioavailability of cimetidine in humans. J. Pharm. Sci. 69:1980;394-398
53. Sandborn W.J., Forland S.C., Cutler R.E., Strong R.M. Pharmacokinetics and pharmacodynamics of oral and intravenous cimetidine in seriously ill patients. J. Clin. Pharmacol. 30:1990;568-571
54. Somogyi A., Gugler R. Clinical pharmacokinetics of cimetidine. Clin. Pharmacokinet. 8:1983;463-495
55. Takamatsu N., Kim O.N., Welage L.S., Idkaidek N.M., Hayashi Y., Barnett J., Yamamoto R., Lipka E., Lennernas H., Hussain A., Lesko L., Amidon G.L. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm. Res. 18:2001;742-744
56. Pade V., Stavchansky S. Link between drug absorption solubility and permeability measurements in Caco-2 cells. J. Pharm. Sci. 87:1998;1604-1607
57. Nauta E.H., Mattie H. Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clin. Pharmacol. Ther. 20:1976;98-108
58. Spino M., Chai R.P., Isles A.F., Thiessen J.J., Tesoro A., Gold R., MacLeod S.M. Cloxacillin absorption and disposition in cystic fibrosis. J. Pediatr. 105:1984;829-835
59. Persson K., Hammarlund-Udenaes M., Mortimer O., Rane A. The postoperative pharmacokinetics of codeine. Eur. J. Clin. Pharmacol. 42:1992;663-666
60. Yue Q.Y., Svensson J.O., Sjoqvist F., Sawe J. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 31:1991;643-647
61. Bittner B., Guenzi A., Fullhardt P., Zuercher G., Gonzalez R.C., Mountfield R.J. Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. Arzneimittelforschung. 52:2002;684-688
62. Ferron G.M., Rochdi M., Jusko W.J., Scherrmann J.M. Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J. Clin. Pharmacol. 36:1996;874-883
63. Rochdi M., Sabouraud A., Girre C., Venet R., Scherrmann J.M. Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur. J. Clin. Pharmacol. 46:1994;351-354
64. Matthias M., Sohr R., Preiss R., Brockmann B. Bioavailability of cyclophosphamide following oral administration in high doses. Onkologie. 7:1984;48-49
65. Struck R.F., Alberts D.S., Horne K., Phillips J.G., Peng Y.M., Roe D.J. Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial. Cancer Res. 47:1987;2723-2726
66. Wagner T., Fenneberg K. Pharmacokinetics and bioavailability of cyclophosphamide from oral formulations. Arzneimittelforschung. 34:1984;313-316
67. Pieters F.A., Zuidema J. The absolute oral bioavailability of dapsone in dogs and humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 25:1987;396-400
68. Venkatesan K. Clinical pharmacokinetic considerations in the treatment of patients with leprosy. Clin. Pharmacokinet. 16:1989;365-386
69. Wiedmann T.S., Kamel L. Examination of the solubilization of drugs by bile salt micelles. J. Pharm. Sci. 91:2002;1743-1764
70. ACD/pKa Database, http://www.scienceserve.com/software/acd/acd_pka_db. htm.
71. Divoll M., Greenblatt D.J., Ochs H.R., Shader R.I. Absolute bioavailability of oral and intramuscular diazepam: effects of age and sex. Anesth. Analg. 62:1983;1-8
72. Ochs H.R., Otten H., Greenblatt D.J., Dengler H.J. Diazepam absorption: effects of age, sex, and Billroth gastrectomy. Dig. Dis. Sci. 27:1982;225-230
73. Beveridge T., Nuesch E., Ohnhaus E.E. Absolute bioavailability of digoxin tablets. Arzneimittelforschung. 28:1978;701-703
74. Greenblatt D.J., Smith T.W., Koch-Weser J. Bioavailability of drugs: the digoxin dilemma. Clin. Pharmacokinet. 1:1976;36-51
75. Hinderling P.H., Hartmann D. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther. Drug Monit. 13:1991;381-401
76. Iisalo E. Clinical pharmacokinetics of digoxin. Clin. Pharmacokinet. 2:1977;1-16
77. Mooradian A.D. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. Clin. Pharmacokinet. 15:1988;165-179
78. Johnson B.F., O'Grady J., Sabey G.A., Bye C. Effect of a standard breakfast on digoxin absorption in normal subjects. Clin. Pharmacol. Ther. 23:1978;315-319
79. Yu L.X. An integrated model for determining causes of poor oral drug absorption. Pharm. Res. 16:1999;1883-1887
80. Huffman D.H., Manion C.V., Azarnoff D.L. Absorption of digoxin from different oral preparations in normal subjects during steady state. Clin. Pharmacol. Ther. 16:1974;310-317
81. Fromm M.F. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:2000;69-74
82. Riond J.L., Riviere J.E. Pharmacology and toxicology of doxycycline. Vet. Hum. Toxicol. 30:1988;431-443
83. Aellig W.H., Nuesch E. Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. Int. J. Clin. Pharmacol. Biopharm. 15:1977;106-112
84. Ekbom K., Krabbe A.E., Paalzow G., Paalzow L., Tfelt-Hansen P., Waldenlind E. Optimal routes of administration of ergotamine tartrate in cluster headache patients. A pharmacokinetic study. Cephalalgia. 3:1983;15-20
85. Ibraheem J.J., Paalzow L., Tfelt-Hansen P. Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers. Br. J. Clin. Pharmacol. 16:1983;695-699
86. Perrin V.L. Clinical pharmacokinetics of ergotamine in migraine and cluster headache. Clin. Pharmacokinet. 10:1985;334-352
87. Butzler J.P., Vanhoof R., Clumeck N., de Mol P., Vanderlinden M.P., Yourassowsky E. Clinical and pharmacological evaluation of different preparations of oral erythromycin. Chemotherapy. 25:1979;367-372
88. Ehrenpreis E.D., Zaitman D., Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmacokinetic analysis. Aliment Pharmacol. Ther. 12:1998;373-376
89. Mather L.E., Austin K.L., Philpot C.R., McDonald P.J. Absorption and bioavailability of oral erythromycin. Br. J. Clin. Pharmacol. 12:1981;131-140
90. Somogyi A.A., Bochner F., Hetzel D., Williams D.B. Evaluation of the intestinal absorption of erythromycin in man: absolute bioavailability and comparison with enteric coated erythromycin. Pharm. Res. 12:1995;149-154
91. Brammer K.W., Farrow P.R., Faulkner J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12:(Suppl. 3):1990;S318-S326
92. Debruyne D., Ryckelynck J.P. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:1993;10-27
93. Shiba K., Saito A., Miyahara T. Safety and pharmacokinetics of single oral and intravenous doses of fluconazole in healthy subjects. Clin. Ther. 12:1990;206-215
94. Tett S., Moore S., Ray J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob. Agents Chemother. 39:1995;1835-1841
95. Uch A.S. Intestinal Uptake of Azole Antifungals in Rats. 1999;Department of Biochemistry, Pharmaceutics and Food Chemistry, Johann Wolfgang Goethe University, Frankfurt
96. Grahnen A., Hammarlund M., Lundqvist T. Implications of intraindividual variability in bioavailability studies of furosemide. Eur. J. Clin. Pharmacol. 27:1984;595-602
97. Hammarlund M.M., Paalzow L.K., Odlind B. Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. Eur. J. Clin. Pharmacol. 26:1984;197-207
98. Lee M.G., Chiou W.L. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J. Pharmacokinet. Biopharm. 11:1983;623-640
99. McCrindle J.L., Li Kam Wa T.C., Barron W., Prescott L.F. Effect of food on the absorption of frusemide and bumetanide in man. Br. J. Clin. Pharmacol. 42:1996;743-746
100. Murray M.D., Haag K.M., Black P.K., Hall S.D., Brater D.C. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 17:1997;98-106
101. Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung. 38:1988;160-163
102. Avdeef A., Berger C.M., Brownell C. pH-metric solubility. 2 Correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. Pharm. Res. 17:2000;85-89
103. Bates T.R., Pieniaszek H.J. Jr., Sequeira J.A., Rasmussen J.E. Gastrointestinal absorption of griseofulvin from corn oil-in-water emulsions: effect of amount of corn oil ingested in man. Arch. Dermatol. 113:1977;302-306
104. Chiou W.L., Riegelman S. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 60:1971;1376-1380
105. Ogunbona F.A., Smith I.F., Olawoye O.S. Fat contents of meals and bioavailability of griseofulvin in man. J. Pharm. Pharmacol. 37:1985;283-284
106. Shepherd A.M., Ludden T.M., McNay J.L., Lin M.S. Hydralazine kinetics after single and repeated oral doses. Clin. Pharmacol. Ther. 28:1980;804-811
107. Talseth T. Studies on hydralazine. III. Bioavailability of hydralazine in man. Eur. J. Clin. Pharmacol. 10:1976;395-401
108. Cheng H., Rogers J.D., Demetriades J.L., Holland S.D., Seibold J.R., Depuy E. Pharmacokinetics and bioinversion of ibuprofen enantiomers in humans. Pharm. Res. 11:1994;824-830
109. Martin W., Koselowske G., Toberich H., Kerkmann T., Mangold B., Augustin J. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm. Drug Dispos. 11:1990;265-278
110. Tan S.C., Patel B.K., Jackson S.H., Swift C.G., Hutt A.J. Stereoselectivity of ibuprofen metabolism and pharmacokinetics following the administration of the racemate to healthy volunteers. Xenobiotica. 32:2002;683-697
111. Carver P.L., Fleisher D., Zhou S.Y., Kaul D., Kazanjian P., Li C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm. Res. 16:1999;718-724
112. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294
113. Yeh K.C., Stone J.A., Carides A.D., Rolan P., Woolf E., Ju W.D. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis. J. Pharm. Sci. 88:1999;568-573
114. Robertson D.R., Wood N.D., Everest H., Monks K., Waller D.G., Renwick A.G., George C.F. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br. J. Clin. Pharmacol. 28:1989;61-69
115. Sasahara K., Nitanai T., Habara T., Morioka T., Nakajima E. Dosage form design for improvement of bioavailability of levodopa II: bioavailability of marketed levodopa preparations in dogs and Parkinsonian patients. J. Pharm. Sci. 69:1980;261-265
116. Back D.J., Grimmer S.F., Rogers S., Stevenson P.J., Orme M.L. Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. Contraception. 36:1987;471-479
117. Grimmer S.F., Back D.J., Orme M.L., Cowie A., Gilmore I., Tjia J. The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception. 33:1986;51-59
118. Maxon H.R., Ritschel W.A., Volle C.P., Eldon M.A., Chen I.W., Fernandez M.F., Cline J., Mayfield G. Pilot study on the absolute and relative bioavailability of Synthroid and Levothroid, two brands of sodium levothyroxine. Int. J. Clin. Pharmacol. Ther. Toxicol. 21:1983;379-382
119. Hasselstrom K., Siersbaek-Nielsen K., Lumholtz I.B., Faber J., Kirkegaard C., Friis T. The bioavailability of thyroxine and 3,5,3′-triiodothyronine in normal subjects and in hyper- and hypothyroid patients. Acta Endocrinol. (Copenh). 110:1985;483-486
120. Hays M.T., Nielsen K.R. Human thyroxine absorption: age effects and methodological analyses. Thyroid. 4:1994;55-64
121. Marathe P.H., Wen Y., Norton J., Greene D.S., Barbhaiya R.H., Wilding I.R. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br. J. Clin. Pharmacol. 50:2000;325-332
122. Pentikainen P.J., Neuvonen P.J., Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur. J. Clin. Pharmacol. 16:1979;195-202
123. Scheen A.J. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet. 30:1996;359-371
124. Myhre E., Rugstad H.E., Hansen T. Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7:1982;221-233
125. Skerjanec A., Campbell N.R., Robertson S., Tam Y.K. Pharmacokinetics and presystemic gut metabolism of methyldopa in healthy human subjects. J. Clin. Pharmacol. 35:1995;275-280
126. Idkaidek N.M., Najib N.M. Enhancement of oral absorption of metronidazole suspension in humans. Eur. J. Pharm. Biopharm. 50:2000;213-216
127. Lamp K.C., Freeman C.D., Klutman N.E., Lacy M.K. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin. Pharmacokinet. 36:1999;353-373
128. Urtasun R.C., Rabin H.R., Partington J. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously. Surgery. 93:1983;145-148
129. Viracept® prescribing information, Agouron Pharmaceuticals, Inc.
130. Bode H., Brendel E., Ahr G., Fuhr U., Harder S., Staib A.H. Investigation of nifedipine absorption in different regions of the human gastrointestinal (GI) tract after simultaneous administration of 13C- and 12C-nifedipine. Eur. J. Clin. Pharmacol. 50:1996;195-201
131. Echizen H., Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin. Pharmacokinet. 11:1986;425-449
132. Rashid T.J., Martin U., Clarke H., Waller D.G., Renwick A.G., George C.F. Factors affecting the absolute bioavailability of nifedipine. Br. J. Clin. Pharmacol. 40:1995;51-58
133. Hoener B., Patterson S.E. Nitrofurantoin disposition. Clin. Pharmacol. Ther. 29:1981;808-816
134. Eandi M., Viano I., Ricci Gamalero S. Absolute bioavailability of paracetamol after oral or rectal administration in healthy volunteers. Arzneimittelforschung. 34:1984;903-907
135. Rawlins M.D., Henderson D.B., Hijab A.R. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur. J. Clin. Pharmacol. 11:1977;283-286
136. Tukker J.J., Sitsen J.M., Gusdorf C.F. Bioavailability of paracetamol after oral administration to healthy volunteers. Influence of caffeine on rate and extent of absorption. Pharm. Weekl. Sci. 8:1986;239-243
137. Ameer B., Divoll M., Abernethy D.R., Greenblatt D.J., Shargel L. Absolute and relative bioavailability of oral acetaminophen preparations. J. Pharm. Sci. 72:1983;955-958
138. Kukovetz W.R., Beubler E., Kreuzig F., Moritz A.J., Nirnberger G., Werner-Breitenecker L. Bioavailability and pharmacokinetics of D-penicillamine. J. Rheumatol. 10:1983;90-94
139. Netter P., Bannwarth B., Pere P., Nicolas A. Clinical pharmacokinetics of D-penicillamine. Clin. Pharmacokinet. 13:1987;317-333
140. Wiesner R.H., Dickson E.R., Carlson G.L., McPhaul L.W., Go V.L. The pharmacokinetics of D-penicillamine in man. J. Rheumatol. Suppl. 7:1981;51-55
141. Nelson E., Powell J.R., Conrad K., Likes K., Byers J., Baker S., Perrier D. Phenobarbital pharmacokinetics and bioavailability in adults. J. Clin. Pharmacol. 22:1982;141-148
142. Frick A., Moller H., Wirbitzki E. Biopharmaceutical characterization of oral immediate-release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. Eur. J. Pharm. Biopharm. 46:1998;305-311
143. Josefsson K., Bergan T. Pharmacokinetics of phenoxymethylpenicillin in volunteers. Chemotherapy. 28:1982;241-246
144. Estruch J., Galdames D., Martinetti A., Saavedra I. Phenytoin pharmacokinetics in young and older adults. Rev. Med. Chil. 120:1992;1106-1109
145. Gugler R., Manion C.V., Azarnoff D.L. Phenytoin: pharmacokinetics and bioavailability. Clin. Pharmacol. Ther. 19:1976;135-142
146. Hirji M.R., Measuria H., Kuhn S., Mucklow J.C. A comparative study of the bioavailability of five different phenytoin preparations. J. Pharm. Pharmacol. 37:1985;570-572
147. Bergrem H., Grottum P., Rugstad H.E. Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur. J. Clin. Pharmacol. 24:1983;415-419
148. Ferry J.J., Horvath A.M., Bekersky I., Heath E.C., Ryan C.F., Colburn W.A. Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses. J. Clin. Pharmacol. 28:1988;81-87
149. Tauber U., Haack D., Nieuweboer B., Kloss G., Vecsei P., Wendt H. The pharmacokinetics of fluocortolone and prednisolone after intravenous and oral administration. Int. J. Clin. Pharmacol. Ther. Toxicol. 22:1984;48-55
150. Mihaly G.W., Ward S.A., Edwards G., Nicholl D.D., Orme M.L., Breckenridge A.M. Pharmacokinetics of primaquine in man. I. Studies of the absolute bioavailability and effects of dose size. Br. J. Clin. Pharmacol. 19:1985;745-750
151. Paton D.M., Webster D.R. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin. Pharmacokinet. 10:1985;477-497
152. Taylor G., Houston J.B., Shaffer J., Mawer G. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br. J. Clin. Pharmacol. 15:1983;287-293
153. Keller F., Kunzendorf U., Walz G., Haller H., Offermann G. Saturable first-pass kinetics of propranolol. J. Clin. Pharmacol. 29:1989;240-245
154. Takamatsu N., Welage L.S., Idkaidek N.M., Liu D.Y., Lee P.I., Hayashi Y., Rhie J.K., Lennernas H., Barnett J.L., Shah V.P., Lesko L., Amidon G.L. Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. Pharm. Res. 14:1997;1127-1132
155. Potthast H. ZL-Untersuchung von Propranolol Präparaten. Pharmazeutische Zeitung. 146:2001
156. Kampmann J., Skovsted L. The pharmacokinetics of propylthiouracil. Acta Pharmacol. Toxicol. (Copenh). 35:1974;361-369
157. Kampmann J.P., Hansen J.M. Clinical pharmacokinetics of antithyroid drugs. Clin. Pharmacokinet. 6:1981;401-428
158. Ellard G.A. Absorption, metabolism and excretion of pyrazinamide in man. Tubercle. 50:1969;144-158
159. Aquilonius S.M., Eckernas S.A., Hartvig P., Lindstrom B., Osterman P.O. Pharmacokinetics and oral bioavailability of pyridostigmine in man. Eur. J. Clin. Pharmacol. 18:1980;423-428
160. Aquilonius S.M., Hartvig P. Clinical pharmacokinetics of cholinesterase inhibitors. Clin. Pharmacokinet. 11:1986;236-249
161. Breyer-Pfaff U., Maier U., Brinkmann A.M., Schumm F. Pyridostigmine kinetics in healthy subjects and patients with myasthenia gravis. Clin. Pharmacol. Ther. 37:1985;495-501
162. Zempleni J., Galloway J.R., McCormick D.B. Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. Am. J. Clin. Nutr. 63:1996;54-66
163. Koup J.R., Williams-Warren J., Viswanathan C.T., Weber A., Smith A.L. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther. Drug Monit. 8:1986;17-22
164. Loos U., Musch E., Jensen J.C., Mikus G., Schwabe H.K., Eichelbaum M. Pharmacokinetics of oral and intravenous rifampicin during chronic administration. Klin. Wochenschr. 63:1985;1205-1211
165. Data-base Merck KGaA.
166. Boulton D.W., Fawcett J.P. Enantioselective disposition of salbutamol in man following oral and intravenous administration. Br. J. Clin. Pharmacol. 41:1996;35-40
167. Goldstein D.A., Tan Y.K., Soldin S.J. Pharmacokinetics and absolute bioavailability of salbutamol in healthy adult volunteers. Eur. J. Clin. Pharmacol. 32:1987;631-634
168. Morgan D.J., Paull J.D., Richmond B.H., Wilson-Evered E., Ziccone S.P. Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate. Br. J. Clin. Pharmacol. 22:1986;587-593
169. Kupferschmidt H.H., Fattinger K.E., Ha H.R., Follath F., Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:1998;355-359
170. Dudley M.N., Graham K.K., Kaul S., Geletko S., Dunkle L., Browne M., Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:1992;480-485
171. Rana K.Z., Dudley M.N. Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33:1997;276-284
172. Zerit prescribing information, Bristol-Meyers Squibb.
173. Chin T.W., Vandenbroucke A., Fong I.W. Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients. Antimicrob. Agents Chemother. 39:1995;28-33
174. Dahlan R., McDonald C., Sunderland V.B. Solubilities and intrinsic dissolution rates of sulphamethoxazole and trimethoprim. J. Pharm. Pharmacol. 39:1987;246-251
175. Klepser M.E., Zhu Z., Nicolau D.P., Banevicius M.A., Belliveau P.P., Ross J.W., Broisman L., Quintiliani R., Nightingale C.H. Oral absorption of trimethoprim-sulfamethoxazole in patients with AIDS. Pharmacotherapy. 16:1996;656-662
176. Fuder H., Herzog R., Vaupel W., Wetzelsberger N., Lucker P.W. Study on the absolute bioavailability of quinine and theophylline from tablets after single dose oral administration as compared to intravenous infusion in healthy male non-smoking volunteers. Methods Find Exp. Clin. Pharmacol. 16:1994;651-660
177. Kaumeier H.S., Kehrhahn O.H., Neugebauer G., Schuppan D., Schwarz J.A., Staib A.H. A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets. Arzneimittelforschung. 34:1984;92-95
178. Steinijans V.W., Schulz H.U., Bohm A., Beier W. Absolute bioavailability of theophylline from a sustained-release formulation using different intravenous reference infusions. Eur. J. Clin. Pharmacol. 33:1987;523-526
179. Tallaksen C.M., Sande A., Bohmer T., Bell H., Karlsen J. Kinetics of thiamin and thiamin phosphate esters in human blood, plasma and urine after 50 mg intravenously or orally. Eur. J. Clin. Pharmacol. 44:1993;73-78
180. Zaccara G., Messori A., Moroni F. Clinical pharmacokinetics of valproic acid, 1988. Clin. Pharmacokinet. 15:1988;367-389
181. Blum M.R., Liao S.H., Good S.S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:1988;189-194
182. Macnab K.A., Gill M.J., Sutherland L.R., De Boer Visser N., Church D. Erratic zidovudine bioavailability in HIV seropositive patients. J. Antimicrob. Chemother. 31:1993;421-428
183. Alberts M.K., Clarke C.R., MacAllister C.G., Homer L.M. Pharmacokinetics of acetazolimide after intravenous and oral administration in horses. Am. J. Vet. Res. 61:2000;965-968
184. Van Os E.C., Zins B.J., Sandborn W.J., Mays D.C., Tremaine W.J., Mahoney D.W., Zinsmeister A.R., Lipsky J.J. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut. 39:1996;63-68
185. Workman P., White R.A., Walton M.I., Owen L.N., Twentyman P.R. Preclinical pharmacokinetics of benznidazole. Br. J. Cancer. 50:1984;291-303
186. Grimaldi R., Perucca E., Ruberto G., Gelmi C., Trimarchi F., Hollmann M., Crema A. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur. J. Clin. Pharmacol. 29:1986;735-737
187. Knupp C.A., Shyu W.C., Morgenthien E.A., Lee J.S., Barbhaiya R.H. Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog. Pharm. Res. 10:1993;1157-1164
188. Shelton M.J., O'Donnell A.M., Morse G.D. Didanosine. Ann. Pharmacother. 26:1992;660-670
189. http://aidsinfo.nih.gov/document/data/drug_lib/technical/drug_tech_0016. html.
190. de Groot A.N., Vree T.B., Hekster Y.A., van den Biggelaar-Martea M., van Dongen P.W., van Roosmalen J. Pharmacokinetics and bioavailability of oral ergometrine in male volunteers. Biopharm. Drug Dispos. 15:1994;65-73
191. Mantyla R., Kleimola T., Kanto J. Methylergometrine (methylergonovine) concentrations in the human plasma and urine. Int. J. Clin. Pharmacol. Biopharm. 16:1978;254-257
192. el Sayed M.A., Loscher W., Frey H.H. Pharmacokinetics of ethosuximide in the dog. Arch. Int. Pharmacodyn. Ther. 234:1978;180-192
193. Patel I.H., Levy R.H., Bauer T.G. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration. Epilepsia. 16:1975;705-716
194. Zent C., Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tuber Lung Dis. 76:1995;109-113
195. Bannwarth B., Pehourcq F., Lequen L. Pharmacokinetics of methotrexate in rheumatoid arthritis: therapeutic implications. Therapie. 52:1997;129-132
196. Campbell M.A., Perrier D.G., Dorr R.T., Alberts D.S., Finley P.R. Methotrexate: bioavailability and pharmacokinetics. Cancer Treat Rep. 69:1985;833-838
197. Herman R.A., Veng-Pedersen P., Hoffman J., Koehnke R., Furst D.E. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J. Pharm. Sci. 78:1989;165-171
198. Kozloski G.D., De Vito J.M., Kisicki J.C., Johnson J.B. The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers. Arthritis Rheum. 35:1992;761-764
199. Lamson M.J., Sabo J.P., MacGregor T.R., Pav J.W., Rowland L., Hawi A., Cappola M., Robinson P. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm. Drug Dispos. 20:1999;285-291
200. Paulos C., Paredes J., Vasquez I., Thambo S., Arancibia A., Gonzalez-Martin G. Pharmacokinetics of a nitrofuran compound, nifurtimox, in healthy volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 27:1989;454-457
201. Middleton H.M. 3rd. In vivo absorption and phosphorylation of pyridoxine. HCl in rat jejunum. Gastroenterology. 76:1979;43-49
202. Edwards G., Breckenridge A.M. Clinical pharmacokinetics of anthelmintic drugs. Clin. Pharmacokinet. 15:1988;67-93
203. Jung H., Medina L., Garcia L., Fuentes I., Moreno-Esparza R. Absorption studies of albendazole and some physicochemical properties of the drug and its metabolite albendazole sulphoxide. J. Pharm. Pharmacol. 50:1998;43-48
204. Lange H., Eggers R., Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur. J. Clin. Pharmacol. 34:1988;315-317
205. Merino G., Alvarez A.I., Prieto J.G., Kim R.B. The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab. Dispos. 30:2002;365-369
206. Nagy J., Schipper H.G., Koopmans R.P., Butter J.J., Van Boxtel C.J., Kager P.A. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am. J. Trop. Med. Hyg. 66:2002;260-263
207. Burch J.E., Herries D.G. The demethylation of amitriptyline administered by oral and intramuscular routes. Psychopharmacology (Berlin). 80:1983;249-253
208. Vandel B., Sandoz M., Vandel S., Allers G., Volmat R. Biotransformation of amitriptyline in depressive patients: urinary excretion of seven metabolites. Eur. J. Clin. Pharmacol. 22:1982;239-245
209. German Standardinformationen für Klinikapotheker, Amineurin®, Hexal AG.
210. Ezzet F., van Vugt M., Nosten F., Looareesuwan S., White N.J. Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob. Agents Chemother. 44:2000;697-704
211. Karbwang J., Na-Bangchang K., Congpuong K., Molunto P., Thanavibul A. Pharmacokinetics and bioavailability of oral and intramuscular artemether. Eur. J. Clin. Pharmacol. 52:1997;307-310
212. Navaratnam V., Mansor S.M., Sit N.W., Grace J., Li Q., Olliaro P. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39:2000;255-270
213. White N.J., van Vugt M., Ezzet F. Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine. Clin. Pharmacokinet. 37:1999;105-125
214. Volz-Zang C., Waldhauser T., Schulte B., Palm D. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. Eur. J. Clin. Pharmacol. 49:1995;45-49
215. Huang S.M., Athanikar N.K., Sridhar K., Huang Y.C., Chiou W.L. Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults. Eur. J. Clin. Pharmacol. 22:1982;359-365
216. Koytchev R., Alken R.G., Kirkov V., Neshev G., Vagaday M., Kunter U. Absolute bioavailability of chlorpromazine, promazine and promethazine. Arzneimittelforschung. 44:1994;121-125
217. Yeung P.K., Hubbard J.W., Korchinski E.D., Midha K.K. Pharmacokinetics of chlorpromazine and key metabolites. Eur. J. Clin. Pharmacol. 45:1993;563-569
218. Lettieri J.T., Rogge M.C., Kaiser L., Echols R.M., Heller A.H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 36:1992;993-996
219. Owens R.C. Jr., Patel K.B., Banevicius M.A., Quintiliani R., Nightingale C.H., Nicolau D.P. Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS. Antimicrob. Agents Chemother. 41:1997;1508-1511
220. Vance-Bryan K., Guay D.R., Rotschafer J.C. Clinical pharmacokinetics of ciprofloxacin. Clin. Pharmacokinet. 19:1990;434-461
221. Bergstrom C.A., Strafford M., Lazorova L., Avdeef A., Luthman K., Artursson P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46:2003;558-570
222. www.pion-inc.com.
223. Holdiness M.R. Clinical pharmacokinetics of clofazimine. A review. Clin. Pharmacokinet. 16:1989;74-85
224. Schaad-Lanyi Z., Dieterle W., Dubois J.P., Theobald W., Vischer W. Pharmacokinetics of clofazimine in healthy volunteers. Int. J. Lepr. Other Mycobact. Dis. 55:1987;9-15
225. Balant-Gorgia A.E., Gex-Fabry M., Balant L.P. Clinical pharmacokinetics of clomipramine. Clin. Pharmacokinet. 20:1991;447-462
226. Peters M.D. 2nd, Davis S.K., Austin L.S. Clomipramine: an antiobsessional tricyclic antidepressant. Clin. Pharm. 9:1990;165-178
227. Brophy T.R., McCafferty J., Tyrer J.H., Eadie M.J. Bioavailability of oral dexamethasone during high dose steroid therapy in neurological patients. Eur. J. Clin. Pharmacol. 24:1983;103-108
228. Duggan D.E., Yeh K.C., Matalia N., Ditzler C.A., McMahon F.G. Bioavailability of oral dexamethasone. Clin. Pharmacol. Ther. 18:1975;205-209
229. O'Sullivan B.T., Cutler D.J., Hunt G.E., Walters C., Johnson G.F., Caterson I.D. Pharmacokinetics of dexamethasone and its relationship to dexamethasone suppression test outcome in depressed patients and healthy control subjects. Biol. Psychiatry. 41:1997;574-584
230. Toth G.G., Kloosterman C., Uges D.R., Jonkman M.F. Pharmacokinetics of high-dose oral and intravenous dexamethasone. Ther. Drug Monit. 21:1999;532-535
231. www.medicaltribune.de.
232. Mouly S., Lown K.S., Kornhauser D., Joseph J.L., Fiske W.D., Benedek I.H., Watkins P.B. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin. Pharmacol. Ther. 72:2002;1-9
233. Back D.J., Madden S., Orme M.L. Gastrointestinal metabolism of contraceptive steroids. Am. J. Obstet. Gynecol. 163:1990;2138-2145
234. Finglas P.M., Witthoft C.M., Vahteristo L., Wright A.J., Southon S., Mellon F.A., Ridge B., Maunder P. Use of an oral/intravenous dual-label stable-isotope protocol to determine folic acid bioavailability from fortified cereal grain foods in women. J. Nutr. 132:2002;936-939
235. Menke A., Weimann H.J., Achtert G., Schuster O., Menke G. Absolute bioavailability of folic acid after oral administration of a folic acid tablet formulation in healthy volunteers. Arzneimittelforschung. 44:1994;1063-1067
236. Neugebauer G., Betzien G., Hrstka V., Kaufmann B., von Mollendorff E., Abshagen U. Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int. J. Clin. Pharmacol. Ther. Toxicol. 23:1985;453-460
237. Bogaert M.G. Clinical pharmacokinetics of nitrates. Cardiovasc. Drugs Ther. 8:1994;693-699
238. Noonan P.K., Benet L.Z. The bioavailability of oral nitroglycerin. J. Pharm. Sci. 75:1986;241-243
239. Cheng Y.F., Paalzow L.K., Bondesson U., Ekblom B., Eriksson K., Eriksson S.O., Lindberg A., Lindstrom L. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology (Berlin). 91:1987;410-414
240. Froemming J.S., Lam Y.W., Jann M.W., Davis C.M. Pharmacokinetics of haloperidol. Clin. Pharmacokinet. 17:1989;396-423
241. Holley F.O., Magliozzi J.R., Stanski D.R., Lombrozo L., Hollister L.E. Haloperidol kinetics after oral and intravenous doses. Clin. Pharmacol. Ther. 33:1983;477-484
242. Chang W.H., Lam Y.W., Jann M.W., Chen H. Pharmacokinetics of haloperidol and reduced haloperidol in Chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology (Berlin). 106:1992;517-522
243. Magliozzi J.R., Hollister L.E. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J. Clin. Psychiatry. 46:1985;20-21
244. Straehl P., Galeazzi R.L. Isosorbide dinitrate bioavailability, kinetics, and metabolism. Clin. Pharmacol. Ther. 38:1985;140-149
245. Fung H.L. Pharmacokinetics and pharmacodynamics of isosorbide dinitrate. Am. Heart J. 110:1985;213-216
246. Jiang J., Hu P., Xie H., Chen H., Fan F., Harker A., Johnson M.A. The pharmacokinetics of lamivudine in healthy Chinese subjects. Br. J. Clin. Pharmacol. 48:1999;250-253
247. Johnson M.A., Moore K.H., Yuen G.J., Bye A., Pakes G.E. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:1999;41-66
248. Yuen G.J., Morris D.M., Mydlow P.K., Haidar S., Hall S.T., Hussey E.K. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1995;1174-1180
249. Adams J.G. Pharmacokinetics of levamisole. J. Rheumatol. Suppl. 4:1978;137-142
250. Sahagun A.M., Teran M.T., Garcia J.J., Fernandez N., Sierra M., Diez M.J. Oral bioavailability of levamisole in goats. J. Vet. Pharmacol. Ther. 24:2001;439-442
251. Watson A.D., Sangster N.C., Church D.B., Van Gogh H. Levamisole pharmacokinetics and bioavailability in dogs. Res. Vet. Sci. 45:1988;411-413
252. ® prescribing info, Abbott Laboratories.
253. Dawson M., Allan R.J., Watson T.R. The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. Br. J. Clin. Pharmacol. 14:1982;453-455
254. Dawson M., Braithwaite P.A., Roberts M.S., Watson T.R. The pharmacokinetics and bioavailability of a tracer dose of [3H]-mebendazole in man. Br. J. Clin. Pharmacol. 19:1985;79-86
255. Crevoisier C., Handschin J., Barre J., Roumenov D., Kleinbloesem C. Food increases the bioavailability of mefloquine. Eur. J. Clin. Pharmacol. 53:1997;135-139
256. Bateman D.N., Kahn C., Davies D.S. The pharmacokinetics of metoclopramide in man with observations in the dog. Br. J. Clin. Pharmacol. 9:1980;371-377
257. Wright M.R., Axelson J.E., Rurak D.W., McErlane B., McMorland G.H., Ongley R.C., Tam Y.K., Price J.D. Linearity of metoclopramide kinetics at doses of 5-20 mg. Br. J. Clin. Pharmacol. 26:1988;469-473
258. Taylor W.B., Bateman D.N. Oral bioavailability of high-dose metoclopramide. Eur. J. Clin. Pharmacol. 31:1986;41-44
259. Graffner C., Lagerstrom P.O., Lundborg P., Ronn O. Pharmacokinetics of metoclopramide intravenously and orally determined by liquid chromatography. Br. J. Clin. Pharmacol. 8:1979;469-474
260. Bateman D.N. Clinical pharmacokinetics of metoclopramide. Clin. Pharmacokinet. 8:1983;523-529
261. Hasselstrom J., Sawe J. Morphine pharmacokinetics and metabolism in humans. Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin. Pharmacokinet. 24:1993;344-354
262. Hoskin P.J., Hanks G.W., Aherne G.W., Chapman D., Littleton P., Filshie J. The bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteers. Br. J. Clin. Pharmacol. 27:1989;499-505
263. Roy S.D., Flynn G.L. Solubility behavior of narcotic analgesics in aqueous media: solubilities and dissociation constants of morphine, fentanyl, and sufentanil. Pharm. Res. 6:1989;147-151
264. Westerling D., Persson C., Hoglund P. Plasma concentrations of morphine, morphine-3-glucuronide, and morphine-6-glucuronide after intravenous and oral administration to healthy volunteers: relationship to nonanalgesic actions. Ther. Drug Monit. 17:1995;287-301
265. http://www-vetpharm.unizh.ch/.
266. Clarke C.R., Burrows G.E., MacAllister C.G., Spillers D.K., Ewing P., Lauer A.K. Pharmacokinetics of intravenously and orally administered pyrimethamine in horses. Am. J. Vet. Res. 53:1992;2292-2295
267. Le Liboux A., Duquesne H., Montay G., Chassard D., Pichard E., Thebault J.J., Frydman A., Gaillot J. Pharmacokinetics of pyrimethamine in healthy young volunteers using a new solid phase extraction/HPLC method. Eur. J. Drug Metab. Pharmacokinet., Spec. No. 3. 1991;284-290
268. Krishna S., White N.J. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clin. Implic., Clin. Pharmacokinet. 30:1996;263-299
269. Paintaud G., Alvan G., Ericsson O. The reproducibility of quinine bioavailability. Br. J. Clin. Pharmacol. 35:1993;305-307
270. Hollander D., Muralidhara K.S. Vitamin A1 intestinal absorption in vivo: influence of luminal factors on transport. Am. J. Physiol. 232:1977;E471-E477
271. Reinersdorff D.V., Bush E., Liberato D.J. Plasma kinetics of vitamin A in humans after a single oral dose of [8,9,19-13C]retinyl palmitate. J. Lipid Res. 37:1996;1875-1885
272. Karim A., Zagarella J., Hribar J., Dooley M. Spironolactone. I. Disposition and metabolism. Clin. Pharmacol. Ther. 19:1976;158-169
273. Overdiek H.W., Merkus F.W. Influence of food on the bioavailability of spironolactone. Clin. Pharmacol. Ther. 40:1986;531-536
274. Bergan T., Ortengren B., Westerlund D. Clinical pharmacokinetics of co-trimazine. Clin. Pharmacokinet. 11:1986;372-386
275. Kumar R., Singh A.P., Kapoor M., Rai A.K. Pharmacokinetics, bioavailability and dosage regimen of sulphadiazine (SDZ) in camels (Camelus dromedarius). J. Vet. Pharmacol. Ther. 21:1998;393-399
276. Das K.M., Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1:1976;406-425
277. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin. Pharmacokinet. 10:1985;285-302
278. Lecaillon J.B., Godbillon J., Campestrini J., Naquira C., Miranda L., Pacheco R., Mull R., Poltera A.A. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br. J. Clin. Pharmacol. 45:1998;601-604
279. Dilger K., Eckhardt K., Hofmann U., Kucher K., Mikus G., Eichelbaum M. Chronopharmacology of intravenous and oral modified release verapamil. Br. J. Clin. Pharmacol. 47:1999;413-419
280. Eichelbaum M., Somogyi A., von Unruh G.E., Dengler H.J. Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil. Eur. J. Clin. Pharmacol. 19:1981;133-137
281. Schomerus M., Spiegelhalder B., Stieren B., Eichelbaum M. Physiological disposition of verapamil in man. Cardiovasc. Res. 10:1976;605-612
282. Sandstrom R., Karlsson A., Knutson L., Lennernas H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15:1998;856-862
283. Mungall D.R., Ludden T.M., Marshall J., Hawkins D.W., Talbert R.L., Crawford M.H. Population pharmacokinetics of racemic warfarin in adult patients. J. Pharmacokinet. Biopharm. 13:1985;213-227
284. Williams G., Sinko P. Oral absorption of the HIV proteases inhibitors: a current update. Adv. Drug Deliv. Rev. 39:1999;211-238